Dr. Benjamin J. Martin, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 599
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Ohio State University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
OH license 084357
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Grant Medical Center Columbus, OH
- Mount Carmel East & West Columbus, OH
- Genesis Hospital Zanesville, OH
- Mount Carmel St Ann's Westerville, OH
- Licking Memorial Hospital Newark, OH
Medical groups
- Central Ohio Urology Group, LLC. (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 599
- Services billed
- 13,737
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 5,220 | 30 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,200 | 29 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 461 | 56 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 445 | 58 |
| Established patient office or other outpatient visit, 30-39 minutes | 379 | 289 |
| Insertion of needle into vein for collection of blood sample | 341 | 184 |
| Psa (prostate specific antigen) measurement, total | 271 | 148 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 246 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 236 | 157 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 164 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Gahanna, OH | 650 |
| Abiraterone Acetate | 627 |
| Orgovyx (relugolix) | 330 |
| Finasteride Other prescribers in Gahanna, OH | 234 |
| Tamsulosin Hcl Other prescribers in Gahanna, OH | 199 |
| Nubeqa (darolutamide) | 183 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Gahanna, OH | 154 |
| Xtandi (enzalutamide) | 135 |
| Erleada (apalutamide) | 62 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Gahanna, OH | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 123 payments worth $26,439 in total to this clinician.
| Dendreon Pharmaceuticals LLC | $13,442 |
|---|---|
| Novartis Pharmaceuticals Corporation | $3,440 |
| Ferring Pharmaceuticals Inc. | $3,175 |
| Janssen Biotech, Inc. | $2,412 |
| Avyxa Pharma, LLC | $1,000 |
| Bayer HealthCare Pharmaceuticals Inc. | $918 |
| Janssen Global Services, LLC | $500 |
| Angiodynamics, Inc. | $301 |
| Compensation for services other than consulting (speaking, faculty) | $14,596 |
|---|---|
| Consulting Fee | $8,095 |
| Food and Beverage | $3,447 |
| Travel and Lodging | $301 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Dendreon Pharmaceuticals LLC Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $4,550 |
| Dendreon Pharmaceuticals LLC Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $2,450 |
| Dendreon Pharmaceuticals LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $2,450 |
| Ferring Pharmaceuticals Inc. Oct 20, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,415 |
| Janssen Biotech, Inc. Oct 18, 2025 | Consulting Fee | $1,880 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Consulting Fee | $1,650 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Consulting Fee | $1,650 |
| Dendreon Pharmaceuticals LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,141 |
| Dendreon Pharmaceuticals LLC Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,050 |
| Avyxa Pharma, LLC Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,000 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Angiodynamics, Inc. Dec 12, 2025 | Travel and Lodging NANOKNIFE · OS · travel to NEW YORK, NY · in-kind | $294 |
| Angiodynamics, Inc. Dec 12, 2025 | Travel and Lodging NANOKNIFE · OS · travel to NEW YORK, NY · in-kind | $6.99 |
| Dendreon Pharmaceuticals LLC Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $4,550 |
| Dendreon Pharmaceuticals LLC Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $842 |
| Dendreon Pharmaceuticals LLC Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $195 |
| Ferring Pharmaceuticals Inc. Oct 20, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,415 |
| Janssen Biotech, Inc. Oct 18, 2025 | Consulting Fee | $1,880 |
| Avyxa Pharma, LLC Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,000 |
| Dendreon Pharmaceuticals LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $2,450 |
| Dendreon Pharmaceuticals LLC Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,141 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Consulting Fee | $1,650 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Consulting Fee | $1,650 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $918 |
| Janssen Global Services, LLC Apr 22, 2025 | Consulting Fee | $500 |
| Dendreon Pharmaceuticals LLC Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $2,450 |
| Dendreon Pharmaceuticals LLC Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,050 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 6 companies. The companies reported $475,485 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
Janssen Research & Development, LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232 - ProvONE
Dendreon Pharmaceuticals LLC · NCT06134240 - BAY 1841788, A 2-stage, Lead-in and Randomized, Phase 2, Open-label study of Darolutamide versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men with Hormone-Nave Prostate Cancer
Bayer HealthCare Pharmaceuticals Inc. - A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
Janssen Research & Development, LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC - ARAMON
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.